Poly Medicure shares slide 5% after Q4 net profit drops 28%; declares ₹3.5 dividend

Shares of medtech firm Poly Medicure Ltd on Monday (May 25) tanked 5% after it reported a 27.8% year-on-year decline in net profit for the fourth quarter of FY26 at ₹66.3 crore, compared with ₹91.8 crore in the corresponding quarter last year.Revenue grew 21.3% year-on-year to ₹534.5 crore from ₹440.8 crore a year ago. EBITDA declined 7.8% to ₹110.3 crore in the January-March quarter from ₹120 crore in the year-ago period. EBITDA margin stood at 20.6% compared with 27.1% last year.

As of April 30, 2026, Poly Medicure said cumulative stent deployments crossed around 11,000 units, while commercial sales of drug-eluting balloons (DEB) commenced with positive clinician feedback. The company also achieved sales of 450 dialysis machines during FY26, taking the total installed base to around 1,000 machines.Also Read: Poly Medicure says margins dip was one-off, growth to improve in the second half

The domestic revenue rose 25%, and international revenue increased 19.4%. For FY26, consolidated revenue grew 12.3%, while domestic revenue rose 19.6% and international revenue increased 9.3%. Poly Medicure said it recorded its highest-ever standalone quarterly revenue in Q4 FY26.FY26 standalone operating EBITDA margin stood at 26.8%, near the upper end of its 25-27% guidance range, while FY26 consolidated operating EBITDA margin came in at 24.4%.

The company had liquidity of ₹842.2 crore as of March 31, 2026, while capital expenditure spending during FY26 stood at ₹296 crore. Gross margin expanded by 130 basis points in FY26, supported by improving product mix and cost optimisation initiatives.

Also Read: Poly Medicure sees second-half rebound; eyes FY27 export recovery and product expansion

Poly Medicure launched 35 products during FY26 and said its R&D team strength stood at around 90 employees across India, Italy and the Netherlands. The company reported 399 patents and cash & cash equivalents of ₹842.2 crore for Q4 FY26 and FY26. RoCE stood at 17.4%, while RoIC came in at 21.4%.

The company’s board recommended a dividend of ₹3.5 per equity share of face value ₹5 each for FY26, subject to shareholders’ approval. Shares of Poly Medicure Ltd ended at ₹1,518.00, down by ₹80.75, or 5.05%, on the BSE.